Drug Trial Radar · NCT01816594
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Sep 3, 2013
Primary completion
Feb 18, 2015
Study completion Feb 18, 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Breast International Group; GBG Forschungs GmbH; SOLTI Breast Cancer Research Group
- First posted
- Mar 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer prior to surgery (neo-adjuvant setting).
Conditions
- HER2-positive Newly Diagnosed, Primary Breast Cancer
Interventions
BKM120Drug
Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
TrastuzumabDrug
Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
PaclitaxelDrug
Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
BKM120 PlaceboDrug
Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pCR) Rate at the Time of Surgery - All ParticipantsTime frame: After 6 weeks
- Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Wild Type (WT)Time frame: After 6 weeks
- Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Mutant (MT)Time frame: After 6 weeks
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Offenbach, Germany
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.